MISP-mediated enhancement of pancreatic cancer growth through the Wnt/β-catenin signaling pathway is suppressed by Fisetin

By sjmartinez • September 16, 2024

Fu X, Ma J, Ma F, Guo S, Wang X, Li Y, Tang Y, Qi J, Zhang W, Ye L. MISP-mediated enhancement of pancreatic cancer growth through the Wnt/β-catenin signaling pathway is suppressed by Fisetin. Biochim Biophys Acta Mol Basis Dis. 2024 Sep 13:167515. doi: 10.1016/j.bbadis.2024.167515. Epub ahead of print. PMID: 39278512.

Tags: Fisetin, Hematology/Oncology, MISP, pancreatic cancer, Publications, Tumor growth, Wnt/β-catenin

The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment

Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa[...]

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma

Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang[...]

Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates

Alkassis S, Glaspy JA, Bardia A. Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates. Clin Adv Hematol Oncol. 2025 Jul-Aug;23(5):290-299. PMID: 40728347.